JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Matthew Liava'a
Peter D. Skillington
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnett, S. A.
Right arrow Articles by Skillington, P. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Barnett, S. A.
Right arrow Articles by Skillington, P. D.
Related Collections
Right arrow Cardiac - pharmacology
Right arrow Cardiac - physiology
Right arrow Extracorporeal circulation
Right arrow Valve disease

J Thorac Cardiovasc Surg 2009;138:233-234
© 2009 The American Association for Thoracic Surgery

Brief Clinical Report

Potential for benefits of aprotinin use to outweigh risks in patients undergoing the Ross procedure

Stephen Arthur Barnett, MBBS, FRACS*, Matthew Liava'a, MBBS, Peter D. Skillington, MBBS, FRACS

Royal Melbourne Hospital, Parkville, Melbourne, Victoria, Australia

Received for publication January 25, 2008; accepted for publication February 13, 2008.

* Address for reprints: Stephen Arthur Barnett, MBBS, FRACS, The Royal Melbourne Hospital, Cardiothoracic Surgery, Grattan St, Parkville, Melbourne, Victoria 3050, Australia. (Email: stephenarthurbarnett@gmail.com).

The first 20% of the full text of this article appears below.


   Introduction
 
Recent reports1-3Go of adverse events related to the use of aprotinin during complex cardiac surgery and the sudden suspension of the BART (Blood conservation using antifibrinolytics: A randomized trial in a cardiac surgery population) trial because of excess mortality in the treatment arm4Go highlight the risks of death, acute renal failure, and acute coronary thrombosis during the perioperative period after treatment with this drug. Our concern is that the very real benefits of the drug in terms of reductions in bleeding, need to return to the operating room, and rate of transfusion of blood and blood products2Go may be overlooked as a result . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.